CompletedNCT05650775
EEG markers of children’s response to ADHD medication
About this title
Read the official source — NCT05650775Medication studyAges 7–11United States
Understand this study
Who was this study for?
Listed age limits: 7 years to 11 years.
- Listed locations
- BrooklineSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: February 17, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- Boston Children's Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 7 Years to 11 Years
- Official registry ID
- NCT05650775
- Official title
Show the full official title
Biomarkers of ADHD Treatment Response
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Brookline
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boston Children's Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Concerta and Adderall-XR.
Who was this study for?
Listed age limits: 7 years to 11 years.
